Revance Therapeutics Inc. (RVNC) Stock Price Up 5%
Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) rose 5% on Wednesday . The company traded as high as $13.95 and last traded at $13.79, with a volume of 95,311 shares. The stock had previously closed at $13.13.
RVNC has been the topic of a number of research reports. Zacks Investment Research cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 13th. SunTrust Banks Inc. initiated coverage on shares of Revance Therapeutics in a report on Wednesday, March 23rd. They set a “buy” rating and a $46.00 target price on the stock. Brean Capital reissued a “buy” rating and set a $48.00 target price on shares of Revance Therapeutics in a report on Tuesday, May 24th. Finally, Guggenheim reissued a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a report on Monday, April 11th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Revance Therapeutics has an average rating of “Buy” and an average target price of $39.60.
The firm has a 50 day moving average price of $15.22 and a 200-day moving average price of $18.50. The stock’s market cap is $393.68 million.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.12. During the same period in the prior year, the firm earned ($0.65) EPS. Equities analysts expect that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.
Other hedge funds have recently made changes to their positions in the company. Jennison Associates boosted its stake in shares of Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 603 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 5,492 shares in the last quarter. Finally, Russell Frank Co purchased a new stake in shares of Revance Therapeutics during the fourth quarter valued at $1,384,000.
Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.